ASND

261.23

0.16% 0.42

Dopo l'orario di chiusura: 257.00 -4.23 -1.62%

Ascendis Pharma A S (ASND)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché ASND Giù? Forum Previsione

Precedente Chiudi:

$260.81

Aprire:

$260

Volume 24 ore:

504.93K

Relative Volume:

0.78

Capitalizzazione di mercato:

$17.13B

Reddito:

$1.01B

Utile/perdita netta:

$581.90M

Rapporto P/E:

29.44

EPS:

8.8733

Flusso di cassa netto:

$50.57M

1 W Prestazione:

-3.65%

1M Prestazione:

+2.19%

6M Prestazione:

+8.61%

1 anno Prestazione:

+31.63%

Intervallo 1D:

$258.01

$262.17

Intervallo di 1 settimana:

$258.01

$272.47

Portata 52W:

$186.05

$282.15

Ascendis Pharma A S Stock (ASND) Company Profile

Nome

Ascendis Pharma A S

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

Indirizzo

Dipendente

1,189

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

ASND's Discussions on Twitter

Compare ASND vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ASND Ascendis Pharma A S	261.23	17.11B	1.01B	581.90M	50.57M	8.8733
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-16	Ripresa	Jefferies	Buy
2026-01-28	Iniziato	Barclays	Overweight
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-10-17	Iniziato	Raymond James	Strong Buy
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-05-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-04-16	Iniziato	RBC Capital Mkts	Outperform
2025-01-07	Iniziato	UBS	Buy
2024-09-05	Aggiornamento	Oppenheimer	Perform → Outperform
2024-06-25	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Iniziato	Stifel	Buy
2023-12-20	Iniziato	Jefferies	Buy
2023-06-14	Ripresa	Credit Suisse	Neutral
2023-04-05	Downgrade	Oppenheimer	Outperform → Perform
2023-04-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-04-03	Downgrade	Credit Suisse	Outperform → Neutral
2022-10-20	Iniziato	Goldman	Buy
2022-08-30	Ripresa	Berenberg	Buy
2022-03-28	Ripresa	Wedbush	Outperform
2022-03-15	Aggiornamento	BofA Securities	Neutral → Buy
2022-03-01	Iniziato	Citigroup	Buy
2022-02-14	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-06	Iniziato	Cowen	Market Perform
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-10-20	Downgrade	BofA Securities	Buy → Neutral
2021-03-30	Downgrade	Oppenheimer	Outperform → Perform
2021-03-11	Ripresa	Stifel	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-03-20	Iniziato	Oppenheimer	Outperform
2019-10-11	Iniziato	Morgan Stanley	Overweight
2019-03-25	Iniziato	Evercore ISI	Outperform
2019-01-24	Iniziato	Cantor Fitzgerald	Overweight
2019-01-24	Aggiornamento	Leerink Partners	Mkt Perform → Outperform
2018-06-26	Iniziato	Stifel	Buy
2018-04-02	Reiterato	Leerink Partners	Mkt Perform
2017-05-11	Iniziato	JP Morgan	Overweight
2017-03-09	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-02-09	Iniziato	Credit Suisse	Outperform
2016-09-26	Iniziato	Wedbush	Outperform

Mostra tutto

Ascendis Pharma A S Borsa (ASND) Ultime notizie

11:15 AM

Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media

11:15 AM

11:01 AM

Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga

11:01 AM

09:52 AM

Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga

09:52 AM

07:54 AM

H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com

07:54 AM

07:45 AM

H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com India

07:45 AM

06:03 AM

TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - Investing.com

06:03 AM

03:45 AM

BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India

03:45 AM

03:42 AM

BMO reiterates Ascendis Pharma stock rating on infant trial data - Investing.com

03:42 AM

Sep 09, 2026

Early infant trial hints at spine and growth gains, Ascendis Pharma (NASDAQ: ASND) says - Stock Titan

Sep 09, 2026

Ascendis Pharma SVP & Pao Sold Shares Worth Over $810K - TradingView

Sep 09, 2026

Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - Stock Titan

Sep 09, 2026

Ascendis Pharma (NASDAQ: ASND) prices new employee warrants at $270.09 - Stock Titan

Sep 09, 2026

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 - globenewswire.com

Sep 09, 2026

Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill

Sep 09, 2026

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance

Sep 09, 2026

Sep 08, 2026

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times

Sep 08, 2026

Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan

Sep 08, 2026

Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard

Sep 08, 2026

Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView

Sep 08, 2026

Sep 07, 2026

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times

Sep 07, 2026

Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative

Sep 07, 2026